Ocugen is trading 5% down now at $1.22 after its August 6, 2026 earnings release showed $1.5 million in revenue but a wider $0.07-per-share loss, while investors appear focused on financing-related dilution concerns.
- The company completed $130 million of convertible-note financing, extending its cash runway into 2028 while increasing potential dilution.
- FDA clearance for the OCU410 Phase 3 trial and pipeline updates provide positives, though execution risk remains.